A free seminar has been set down for November 13 in Sydney, with the aim of letting young biotechnology companies into the secrets of developing management strategies that will allow them to survive adverse events. [ + ]

Adelaide company Ellex Medical Lasers yesterday announced it had a signed a contract with Californian manufacturer Lumenis to produce a compact new photocoagulator laser for retinal surgery, the Laserex LP3532. [ + ]

Industry association AusBiotech has today launched a special interest group to drive collaboration between the IT, biotechnology and medical device sectors. [ + ]

Adelaide researchers have made progress on the development of a new gene therapy technique for cystic fibrosis, utilising a naturally occurring detergent in combination with a retroviral delivery vector. [ + ]

A bid by Perth lawyer and financier Farooq Khan to force his way onto the board of Biota Holdings has been rejected by the drug discovery company. [ + ]

CSIRO scientists have combined solar energy and natural gas in a process capable of producing large-scale energy to power Australia's future industrial and domestic needs.

With NSW in the grip of drought a major new study has been launched to determine the mechanisms linking water availability and plant productivity in Australia.

The 2003 Lorne Protein and Cancer Conferences have snared two of the biggest names in medical research as guest speakers next February: 2002 Nobel Laureates Prof Sir Sidney Brenner and Prof Robert Horovitz. [ + ]

The survival rate of children with childhood cancers has increased spectacularly since the early 1960s, from a bleak 10 per cent to around 75 per cent today. One notable exception to the trend is neuroblastoma, with a survival rate below 50 per cent. [ + ]

Acrux has officially opened its new facilities in West Melbourne, kicking off a new phase in the company's growth. [ + ]

Amrad chairman Olaf O'Duill doesn't like it when companies use "cash burn" to absolve themselves of their spending, and wants Amrad to think about cash earned, he told the company's annual general meeting yesterday. [ + ]

The bacteria that infect human beings have disarmed almost the entire modern arsenal of antibiotics. Not long after new antibiotics are deployed, resistance appears almost magically. [ + ]

The Kerry Packer-backed financial services and venture capital (VC) group Challenger International is nearing the end of negotiations to form a biotech VC fund out of Singapore which will trawl for investment opportunities across Asia, Australia and New Zealand, the company revealed on Wednesday. [ + ]

Brisbane biotech company Agenix will begin safety and efficacy trials of its new Thromboview blood-clot imaging technology in healthy human volunteers early next year. [ + ]

Perched at the top of the ABN Amro Building in the heart of Sydney's 'big end' of town, Sean Mordaunt, business development manager with Challenger International's Corporate Superannuation Fund, thrives on the manic energy pulsing through the busy business hub and the harbour below. [ + ]